Luwad, Norpa .
HRN: 25-78-45 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/30/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/30/2024
09/06/2024
IV
4.5g
Q8h
Pneumonia
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes